State of the world today, as revealed by the current New England Journal of Medicine, in a postscript to an article on the efficacy of an antidepressant vs. psychotherapy:
Supported by Bristol-Myers Squibb. Dr. Keller has served as a consultant to or received honorariums from Pfizer, Bristol-Myers Squibb, Forest Laboratories/Parke-Davis, Wyeth - Ayerst, Merck, Janssen, Eli Lilly, Organon, and Pharmacia - Upjohn. He has received research grants from Wyeth - Ayerst, SmithKline Beecham, Upjohn, Pfizer, Bristol-Myers Squibb, Merck, Forest Laboratories, Zeneca, and Organon. He has served on the advisory board of Wyeth - Ayerst, Pfizer, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories/Parke-Davis, Organon, SmithKline Beecham, Merck, Janssen, Mitsubishi Pharmaceuticals, Zeneca, Scirex, and Otsuka. Dr. Klein has served as a consultant to Bristol-Myers Squibb. Dr. Dunner has served as a consultant to Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, and Eli Lilly. He has received research grants from Bristol-Myers Squibb, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Forest Laboratories, Glaxo Wellcome, and Wyeth - Ayerst. He has received speaker's honorariums from Bristol-Myers Squibb, SmithKline Beecham, Glaxo Wellcome, Eli Lilly, Organon, and Wyeth - Ayerst. Dr. Gelenberg has received grants and research support from Bristol-Myers Squibb, Organon, Pfizer, Lilly Research Laboratories, Janssen, Merck Sharp & Dohme, SmithKline Beecham, Wyeth - Ayerst, Hoechst Marion Roussel, and Forest Laboratories. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Pfizer, SmithKline Beecham, Janssen, Lilly, Forest Laboratories, and Parke-Davis. He is a stockholder or has other ownership interest in Pfizer, Warner-Lambert, and Eli Lilly. He has served as a consultant to Eli Lilly, Scios, Forest Laboratories, Parke-Davis, Pfizer, Janus Pharmaceuticals, Best Practice, and Bristol-Myers Squibb. Dr. Markowitz has received speaker's honorariums from Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, and Pfizer. Dr. Nemeroff has been a consultant to or received honorariums from Abbott, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi, Neurocrine Biosciences, Organon, Otsuka, Pfizer, Pharmacia - Upjohn, Sanofi, SmithKline Beecham, Solvay, and Wyeth - Ayerst. He has received research support from Abbott, AstraZeneca, Bristol-Myers Squibb, Forest Laboratories, Janssen, Eli Lilly, Organon, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Solvay, and Wyeth - Ayerst. Dr. Russell has been a consultant to or received honorariums from Abbott, Bristol-Myers Squibb, Janssen, Eli Lilly, Pfizer, and Quintiles. He has received research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Parke-Davis, Pharmacia - Upjohn, Pfizer, SmithKline Beecham, Wyeth - Ayerst, Shire, and Quintiles. Dr. Thase has served as a consultant to Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome/Cerenex Pharmaceuticals, Merck, Organon, Pfizer, Pharmacia - Upjohn, and Wyeth - Ayerst. He has received grant and research support from Bristol-Myers Squibb, Lipha Pharmaceuticals, Merck, Organon, Pharmacia - Upjohn, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Eli Lilly, Forest Pharmaceuticals, Glaxo Wellcome/Cerenex Pharmaceuticals, Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Solvay, and Wyeth - Ayerst. Dr. Trivedi has received research grants from Abbott, Akzo (Organon), Bayer, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Janssen, Johnson & Johnson, MeadJohnson, Parke-Davis, Pfizer, Pharmacia - Upjohn, Solvay, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Bristol-Myers Squibb, Forest Laboratories, Pharmacia - Upjohn, Solvay, and Wyeth - Ayerst. Dr. Zajecka has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Glaxo Wellcome, Organon, Otsuka America, Parke-Davis, Pfizer, Pharmacia - Upjohn, and Sanofi Research. He has served as a consultant to or has served on the advisory board of Abbott, Bristol-Myers Squibb, and Eli Lilly. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, SmithKline Beecham, Upjohn, and Wyeth - Ayerst. Dr. Blalock has served as a consultant to Bristol-Myers Squibb. Dr. DeBattista has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Parke-Davis, Pfizer, Scios, SmithKline Beecham, Wyeth - Ayerst, and Organon. He has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Glaxo Wellcome, Pfizer, the National Alliance for Research on Schizophrenia and Depression, Pharmacia - Upjohn, PharmaPrint/ABA, SmithKline Beecham, and Wyeth - Ayerst. He has served as a consultant to Bristol-Myers Squibb, Eli Lilly, Glaxo Wellcome, and PharmaPrint. Dr. Fawcett has received grants and research support from Abbott, Bristol-Myers Squibb, Glaxo, Eli Lilly, Organon, Pfizer, SmithKline Beecham, Wyeth - Ayerst, and Zeneca. He has served as a consultant to Abbott, Bristol-Myers Squibb, Eli Lilly, EM Industries, Forest Laboratories, Glaxo Wellcome, Pfizer, Pharmacia - Upjohn, and SmithKline Beecham. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Pfizer/Roerig, Pharmacia - Upjohn, SmithKline Beecham, and Wyeth - Ayerst. Dr. Hirschfeld has received grants and research support from Abbott, Bristol-Myers Squibb, Organon, and Pfizer. He has served as a consultant to or on the advisory board of Abbott, Bristol-Myers Squibb, Glaxo Wellcome, Forest Laboratories, Eli Lilly, Pfizer, SmithKline Beecham, Janssen, Organon, Parke-Davis, and Pharmacia - Upjohn. Dr. Kocsis has had research contracts with Bristol-Myers Squibb, Pfizer, Forest Laboratories, Eli Lilly, and Wyeth - Ayerst. He has received speaker's honorariums from Bristol-Myers Squibb, Forest Laboratories, and Eli Lilly. He owns stock in Pfizer and Forest Laboratories. Dr. Kornstein has received research grants from Bristol-Myers Squibb, Pfizer, Eli Lilly, Glaxo Wellcome, Forest Laboratories, Mitsubishi Pharmaceuticals, and Biovail. She has served as a consultant to Bristol-Myers Squibb, Pfizer, Eli Lilly, and Pharmacia - Upjohn. She has received honorariums from Bristol-Myers Squibb, Pfizer, and Glaxo Wellcome. Dr. Ninan has received grants and research support from Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, Pharmacia - Upjohn, SmithKline Beecham, and Solvay. He has served as a consultant to Pfizer, TAPPharma, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Eli Lilly, Forest Laboratories, Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Solvay, Janssen, and Wyeth - Ayerst. Dr. Rothbaum has served as a consultant to Bristol-Myers Squibb and Pfizer. She has been a member of the advisory board of and a speakers' bureau sponsored by Pfizer. Dr. Rush has received grants and research support from Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Novartis, Organon, Pfizer, Pharmacia - Upjohn, SmithKline Beecham, Wyeth - Ayerst, and Zeneca. He has served as a consultant to Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Janssen, Merck, Organon, Pfizer, Pharmacia - Upjohn, and Wyeth - Ayerst. He has been a member of speakers' bureaus sponsored by Abbott, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest Laboratories/Parke-Davis, Glaxo Wellcome, Organon, Pfizer, Pharmacia - Upjohn, and Wyeth - Ayerst. Dr. Schatzberg has served as a consultant to or received honorariums from Abbott, Bristol-Myers Squibb, Corcept Therapeutics, Forest Laboratories, Janssen, Eli Lilly, Merck, Mitsubishi Pharmaceuticals, Organon, Parke-Davis, Pfizer, Pharmacia - Upjohn, Sanofi, Scirex, SmithKline Beecham, Solvay, and Wyeth - Ayerst. He has received research support from Bristol-Myers Squibb, Pfizer, and SmithKline Beecham. He has equity ownership in Corcept, Merck, Pfizer, and Scirex.
Peter |
